A Double-Blind, Placebo-Controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-Metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Trial Profile

A Double-Blind, Placebo-Controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-Metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Male osteoporosis
  • Focus Adverse reactions; Registrational
  • Sponsors Amgen
  • Most Recent Events

    • 14 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2016 The trial was completed in Slovakia (end date: 2016-05-12).
    • 03 Jun 2016 The trial was completed in Latvia (end date: 2016-05-12).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top